AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12015391 — intervention group
Group type: EXPERIMENTAL
Intervention: t-PA (100 mg intravenously over 15 minutes)
Number of subjects: 233
Study 12015391 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously over 15 minutes)
Number of subjects: 233
Study 10480411 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 microg)
Number of subjects: 132
Study 10480411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 10480411 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol and Placebo (both groups)
Number of subjects: 132
Study 10480411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypogonadism
Number of subjects: 132
Study 10480411 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 132
Study 8621278 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CRT (78 Gy in 39 fractions)
Number of subjects: 60
Study 8621278 — intervention group
Group type: COMPARATOR
Intervention: Conven-RT (70 Gy in 35 fractions)
Number of subjects: 60
Study 8621278 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 60
Study 2021378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive procedures directed at changing misinterpretations of bodily sensations
Number of subjects: 0
Study 2021378 — intervention group
Group type: COMPARATOR
Intervention: Cognitive procedures not targeting misinterpretations
Number of subjects: 0
Study 6958191 — intervention group
Group type: EXPERIMENTAL
Intervention: Product feedback (IBI X PTT) during dynamic exercise
Number of subjects: 7
Study 6958191 — intervention group
Group type: EXPERIMENTAL
Intervention: Product feedback (IBI X PTT) at rest
Number of subjects: 7
Study 6958191 — intervention group
Group type: EXPERIMENTAL
Intervention: PTT feedback during isometric exercise
Number of subjects: 7
Study 6958191 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback training for anginal patients
Number of subjects: 7
Study 31623051 — intervention group
Group type: EXPERIMENTAL
Intervention: LOP chemotherapy (asparaginase + vincristine + dexamethasone) combined with IMRT
Number of subjects: 60
Study 31623051 — intervention group
Group type: COMPARATOR
Intervention: CHOP chemotherapy (cyclophosphamide + pirarubicin + vincristine + dexamethasone) combined with IMRT
Number of subjects: 60
Study 31623051 — intervention group
Group type: EXPERIMENTAL
Intervention: LOP chemotherapy combined with IMRT
Number of subjects: 60
Study 31623051 — intervention group
Group type: COMPARATOR
Intervention: CHOP chemotherapy combined with IMRT
Number of subjects: 60
Study 27814309 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine (OMM) bi-weekly for 6 weeks
Number of subjects: 11
Study 27814309 — intervention group
Group type: COMPARATOR
Intervention: Weekly counseling sessions (placebo-control) for 6 weeks
Number of subjects: 11
Study 26387858 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 216
Study 26387858 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE combined with a behavioral approach (NSEB)
Number of subjects: 216
Study 26387858 — intervention group
Group type: COMPARATOR
Intervention: Prescribed physical activity (PPA)
Number of subjects: 216
Study 25064672 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual flavor (single flavor group, n=25-26)
Number of subjects: 151
Study 25064672 — intervention group
Group type: EXPERIMENTAL
Intervention: Variety of flavors (3 different flavors, n=50)
Number of subjects: 151
Study 25064672 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance to the protocol
Number of subjects: 151
Study 25064672 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 151
Study 25064672 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 151
Study 22021102 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 178
Study 22021102 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise programme (SEP)
Number of subjects: 178
Study 22021102 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (PTA plus SEP)
Number of subjects: 178
Study 22021102 — intervention group
Group type: COMPARATOR
Intervention: PTA
Number of subjects: 178
Study 22021102 — intervention group
Group type: COMPARATOR
Intervention: SEP
Number of subjects: 178
Study 22021102 — intervention group
Group type: COMPARATOR
Intervention: PTA plus SEP
Number of subjects: 178
Study 18635705 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (4.5 mg po bid) and domperidone (10 mg po qd)
Number of subjects: 15
Study 17598971 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbiturate coma (Group A, 17 patients)
Number of subjects: 40
Study 17598971 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B, 23 patients)
Number of subjects: 40
Study 15044205 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐gamma 1b (200 microg) thrice weekly for 6 months
Number of subjects: 330
Study 15044205 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐gamma 1b treatment
Number of subjects: 330
Study 12501905 — intervention group
Group type: EXPERIMENTAL
Intervention: Zevin® (generic acyclovir)
Number of subjects: 0
Study 12501905 — intervention group
Group type: COMPARATOR
Intervention: Zovirax® (brand name acyclovir)
Number of subjects: 0
Study 9862943 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission to the chest-pain observation unit (CPU) with a strict protocol including aspirin, heparin, continuous ST-segment monitoring, determination of creatine kinase isoenzyme levels, six hours of observation.
Number of subjects: 424
Study 9862943 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital admission (monitored bed under the care of the cardiology service).
Number of subjects: 424
Study 8092082 — intervention group
Group type: EXPERIMENTAL
Intervention: diet relatively high in fat + 30 mg dexfenfluramine (dF)
Number of subjects: 32
Study 8092082 — intervention group
Group type: COMPARATOR
Intervention: diet relatively high in fat + placebo
Number of subjects: 32
Study 8092082 — intervention group
Group type: COMPARATOR
Intervention: diet relatively high in carbohydrates
Number of subjects: 32
Study 3963358 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia (NA group)
Number of subjects: 50
Study 3963358 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural combined with light general anaesthesia (epidural group)
Number of subjects: 50
Study 30200973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential POCUS-assisted protocol
Number of subjects: 7
Study 30200973 — intervention group
Group type: COMPARATOR
Intervention: Parallel POCUS-assisted protocol
Number of subjects: 7
Study 27771985 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 4752
Study 27771985 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 4752
Study 24877078 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Training (HRT)
Number of subjects: 50
Study 24877078 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Resistance Training (LRT)
Number of subjects: 50
Study 22297080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative antimicrobial prophylaxis alone (cefazolin 1 g before the surgical incision and every 3 h as intraoperative supplements)
Number of subjects: 355
Study 22297080 — intervention group
Group type: COMPARATOR
Intervention: Extended antimicrobial prophylaxis (intraoperative administration plus cefazolin 1 g once after closure and twice daily for 2 postoperative days)
Number of subjects: 355
Study 20501957 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (12,000 IU intravenous administration)
Number of subjects: 36
Study 20501957 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (12,000 IU intravenous administration) in LAD subgroup
Number of subjects: 36
Study 20501957 — intervention group
Group type: COMPARATOR
Intervention: Control (saline administration)
Number of subjects: 36
Study 18595418 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 227
Study 18595418 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion plus nicotine patch
Number of subjects: 227
Study 18651857 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp with sulfadoxine-pyrimethamine (SP)
Number of subjects: 207
Study 18651857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 18651857 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal anaemia (haematocrit <33%)
Number of subjects: 207
Study 18651857 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental malaria
Number of subjects: 207
Study 18651857 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HIV RNA viral load
Number of subjects: 207
Study 15163255 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 956
Study 15163255 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 956
Study 11120523 — intervention group
Group type: COMPARATOR
Intervention: ABO-compatible maternal-fetal dyads
Number of subjects: 1661
Study 11120523 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO-incompatible maternal-fetal dyads
Number of subjects: 1661
Study 11120523 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal blood groups A and B
Number of subjects: 1661
Study 11120523 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal type O and neonate type B
Number of subjects: 1661
Study 11120523 — intervention group
Group type: EXPERIMENTAL
Intervention: Type O mother and type B neonate combinations
Number of subjects: 1661
Study 9339268 — intervention group
Group type: COMPARATOR
Intervention: 75 mg t.i.d. xanomeline
Number of subjects: 343
Study 9339268 — intervention group
Group type: COMPARATOR
Intervention: xanomeline (dose-dependent)
Number of subjects: 343
Study 8471827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (200-300 mg/day)
Number of subjects: 32
Study 8471827 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (200-300 mg/day)
Number of subjects: 32
Study 3535049 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pivampicillin and pivmecillinam
Number of subjects: 96
Study 3535049 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin alone
Number of subjects: 96
Study 31045214 — intervention group
Group type: EXPERIMENTAL
Intervention: Current corrective messages
Number of subjects: 803
Study 31045214 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry Deception + Testimonial messages
Number of subjects: 803
Study 31045214 — intervention group
Group type: COMPARATOR
Intervention: Industry Deception
Number of subjects: 803
Study 31045214 — intervention group
Group type: COMPARATOR
Intervention: Industry Deception + Testimonial
Number of subjects: 803
Study 31038232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) at 10°C for 10 minutes
Number of subjects: 20
Study 31038232 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-body cryotherapy (PBC) at -60°C for 30 seconds, -135°C for 2 minutes
Number of subjects: 20
Study 29975601 — intervention group
Group type: EXPERIMENTAL
Intervention: High quantity of carbohydrate (CHO) at 1.5 g/kg body weight
Number of subjects: 0
Study 29975601 — intervention group
Group type: EXPERIMENTAL
Intervention: Low quantity of carbohydrate (CHO) at 0.8 g/kg body weight
Number of subjects: 0
Study 29975601 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic index (GI) CHO (75)
Number of subjects: 0
Study 29975601 — intervention group
Group type: COMPARATOR
Intervention: Low glycemic index (GI) CHO (40)
Number of subjects: 0
Study 26822146 — intervention group
Group type: EXPERIMENTAL
Intervention: bexarotene 300 mg
Number of subjects: 20
Study 26822146 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 24138546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut oil (n-3:n-6 ratio: 1.3 : 6.1)
Number of subjects: 92
Study 24138546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed oil (n-3:n-6 ratio: 0.6 : 5.7)
Number of subjects: 92
Study 24138546 — intervention group
Group type: COMPARATOR
Intervention: Control group (T2DM-OAD)
Number of subjects: 92
Study 24138546 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oil groups (nut oil and mixed oil)
Number of subjects: 92
Study 22661455 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Satisfaction in the ICU (FS-ICU) and Single-Item Quality of Dying (QOD-1) questionnaires
Number of subjects: 1290
Study 22661455 — intervention group
Group type: EXPERIMENTAL
Intervention: FS-ICU items with low ratings
Number of subjects: 1290
Study 19458961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and aerobic training (4 sessions/week: 2 strength, 2 aerobic) for 16 weeks
Number of subjects: 20
Study 17962429 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline 1 mg twice a day
Number of subjects: 24
Study 17962429 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 14726297 — intervention group
Group type: EXPERIMENTAL
Intervention: EX group (physical training)
Number of subjects: 140
Study 14726297 — intervention group
Group type: COMPARATOR
Intervention: CO group (control)
Number of subjects: 140
Study 11206672 — intervention group
Group type: EXPERIMENTAL
Intervention: CODAS‐Verapamil (200 mg)
Number of subjects: 257
Study 11206672 — intervention group
Group type: EXPERIMENTAL
Intervention: CODAS‐Verapamil (300 mg)
Number of subjects: 257
Study 11206672 — intervention group
Group type: EXPERIMENTAL
Intervention: CODAS‐Verapamil (400 mg)
Number of subjects: 257
Study 11206672 — intervention group
Group type: EXPERIMENTAL
Intervention: CODAS‐Verapamil (bedtime dosing)
Number of subjects: 257
Study 9509195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline and dextran (HSD)
Number of subjects: 20
Study 9509195 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 20
Study 7826932 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological or sexual victimization by male dating partners
Number of subjects: 0
Study 7826932 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of sexual coercion, unwanted sexual touching, psychological abuse, and sexual abuse
Number of subjects: 0
Study 7826932 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized fear of crime
Number of subjects: 0
Study 3279366 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol (0.5 or 1%)
Number of subjects: 0
Study 3279366 — intervention group
Group type: COMPARATOR
Intervention: 0.5% Timolol (Control)
Number of subjects: 0
Study 31818339 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 63
Study 31818339 — intervention group
Group type: COMPARATOR
Intervention: Sham-stimulation (Control)
Number of subjects: 63
Study 30018118 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1,200 IU/day)
Number of subjects: 155
Study 30018118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 26692007 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous melatonin (short-term use)
Number of subjects: 0
Study 26692007 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous melatonin (long-term use)
Number of subjects: 0
Study 26692007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26692007 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous melatonin (in children and adolescents)
Number of subjects: 0
Study 26692007 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous melatonin (in pregnant and breast-feeding women)
Number of subjects: 0
Study 25911117 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidetector row CT (MDCT) with model-based iterative reconstruction (MBIR), no ECG triggering, tube voltage and tube current of 100 kV and 60 mA
Number of subjects: 200
Study 25911117 — intervention group
Group type: COMPARATOR
Intervention: Multidetector row CT (MDCT) with adaptive statistical iterative reconstruction algorithm (ASIR), no ECG triggering, kV and mA tailored on patient BMI
Number of subjects: 200
Study 22982467 — intervention group
Group type: EXPERIMENTAL
Intervention: learner-generated drawing
Number of subjects: 108
Study 20359843 — intervention group
Group type: EXPERIMENTAL
Intervention: diacetylmorphine
Number of subjects: 140
Study 20359843 — intervention group
Group type: EXPERIMENTAL
Intervention: hydromorphone
Number of subjects: 140
Study 18237589 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose <81 mg/dl (hypoglycemia)
Number of subjects: 3491
Study 18237589 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose >199 mg/dl (severe hyperglycemia)
Number of subjects: 3491
Study 18237589 — intervention group
Group type: COMPARATOR
Intervention: Blood glucose 81 to 99 mg/dl (euglycemic group)
Number of subjects: 3491
Study 18237589 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose 81 to 99 mg/dl
Number of subjects: 3491
Study 18237589 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose >199 mg/dl
Number of subjects: 3491
Study 18237589 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose 150 to 199 mg/dl
Number of subjects: 3491
Study 16740516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention designed to reinforce tobacco abstinence
Number of subjects: 765
Study 11863094 — intervention group
Group type: EXPERIMENTAL
Intervention: Original CISCA/VB regimen (100% dose)
Number of subjects: 125
Study 11863094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CISCA/VB regimen (80% dose)
Number of subjects: 125
Study 11863094 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 125
Study 10469180 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A (single viral inactivated concentrate) - 32.5 IU kg-1
Number of subjects: 15
Study 10469180 — intervention group
Group type: COMPARATOR
Intervention: Preparation B (double viral inactivated concentrate) - 27 IU kg-1
Number of subjects: 15
Study 7554704 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg for 1 day and 250 mg for 4 subsequent days
Number of subjects: 0
Study 7554704 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine 60 mg twice daily for 12 days
Number of subjects: 0
Study 7554704 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin and placebo
Number of subjects: 0
Study 2177216 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 400 micrograms day‐1
Number of subjects: 13
Study 2177216 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nedocromil sodium (NDS) 16 mg day‐1
Number of subjects: 13
Study 6986893 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 9
Study 6986893 — intervention group
Group type: COMPARATOR
Intervention: Placebo (substituted for bromocriptine)
Number of subjects: 9
Study 6986893 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (after stopping therapy)
Number of subjects: 9
Study 30496423 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including an educational session, a decision tool, an information booklet, and an online video.
Number of subjects: 18
Study 30496423 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 18
Study 30496423 — intervention group
Group type: COMPARATOR
Intervention: Control group (childcare-as-usual)
Number of subjects: 18
Study 30496423 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 28509812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Number of subjects: 2166
Study 26229119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone intervention
Number of subjects: 365
Study 26229119 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal coaching intervention
Number of subjects: 365
Study 26229119 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 365
Study 23375753 — intervention group
Group type: COMPARATOR
Intervention: Plant sterol-enriched margarine (3.0 g/d of plant sterols)
Number of subjects: 43
Study 23375753 — intervention group
Group type: COMPARATOR
Intervention: Plant stanol-enriched margarine (3.0 g/d of plant stanols)
Number of subjects: 43
Study 23375753 — intervention group
Group type: EXPERIMENTAL
Intervention: Control margarine
Number of subjects: 43
Study 21273909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling exercise (SE) warm-up
Number of subjects: 16
Study 21273909 — intervention group
Group type: COMPARATOR
Intervention: Thrower's 10 warm-up
Number of subjects: 16
Study 19617211 — intervention group
Group type: EXPERIMENTAL
Intervention: Taping of the shoulder
Number of subjects: 33
Study 16969707 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebeccamycin analog 500 mg/m2 IV bolus every 21 days (arm 1)
Number of subjects: 42
Study 16969707 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebeccamycin analog 140 mg/m2 IV bolus daily x 5 days, every 21 days (arm 2)
Number of subjects: 42
Study 16969707 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 42
Study 15136950 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg/day
Number of subjects: 103
Study 15136950 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1700 mg/day
Number of subjects: 103
Study 15136950 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 103
Study 11743513 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-reported health status and QOL scores from the Pediatric Asthma Quality of Life Questionnaire after 12 months of randomization.
Number of subjects: 339
Study 11743513 — intervention group
Group type: EXPERIMENTAL
Intervention: Child's anxiety level, age, sex, and symptom exaggeration/minimization tendencies as predictors of QOL.
Number of subjects: 339
Study 9261762 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 70%
Number of subjects: 109
Study 9261762 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic iodine 2%
Number of subjects: 109
Study 9261762 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline with prednisone infusion
Number of subjects: 109
Study 9261762 — intervention group
Group type: COMPARATOR
Intervention: Prednisone infusion alone
Number of subjects: 109
Study 8410926 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 27
Study 8410926 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 27